AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on ...
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusionAstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback